生产企业：Oligomerix, Inc.
OLX-07010 is the lead investigational compound of Oligomerix, Inc.: an oral, self-administered, once-daily small-molecule drug candidate being developed for Alzheimer's disease (AD) and other progressive neurodegenerative diseases. It has demonstrated an ability to prevent the accumulation of tau protein in multiple animal models and has completed Phase 1a clinical development, demonstrating a favorable safety profile in healthy volunteers.
OLX-07010 is the lead investigational compound of Oligomerix, Inc.: an oral, self-administered, once-daily small-molecule drug candidate being developed for Alzheimer's disease (AD) and other progressive neurodegenerative diseases. It has demonstrated an ability to prevent the accumulation of tau protein in multiple animal models and has completed Phase 1a clinical development, demonstrating a favorable safety profile in healthy volunteers.
Small-molecule inhibitor of tau protein accumulation: prevents the accumulation of tau protein in multiple animal models.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
